Larentine D 5mg/5mg Tablet is a combination medication containing Donepezil hydrochloride 5mg and Memantine hydrochloride 5mg, indicated for the treatment of moderate to severe Alzheimer's disease. Donepezil, a reversible acetylcholinesterase inhibitor, enhances cholinergic function by increasing the concentration of acetylcholine in the brain, thereby improving cognitive function and memory. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, modulates glutamatergic neurotransmission by blocking excessive NMDA receptor activity, which is implicated in neurodegeneration. The synergistic action of these agents targets multiple pathological pathways in Alzheimer's disease, offering symptomatic relief and potential slowing of disease progression. Larentine D is administered orally, with dosing tailored to patient tolerance and clinical response. Common adverse effects may include nausea, dizziness, headache, and gastrointestinal disturbances, while serious side effects are rare but warrant monitoring. Caution is advised in patients with hepatic or renal impairment, cardiac conditions, or seizure disorders. Larentine D should be prescribed under medical supervision, with regular assessment of cognitive status and tolerability to optimize therapeutic outcomes. This combination therapy represents a valuable option in the comprehensive management of Alzheimer's disease, aiming to improve quality of life and functional independence in affected individuals.